Thesis
Ersodetug's fate hinges on whether FDA accepts CGM-based sunRIZE data and whether upLIFT confirms tumor HI efficacy at full enrollment
Ersodetug, an anti-insulin receptor antibody, targets two ultra-rare hyperinsulinism indications — congenital HI and tumor HI — in severely underserved patient populations. The thesis resolves if FDA accepts the CGM-based sunRIZE dataset as sufficient for a congenital HI marketing application, or if upLIFT delivers confirmatory tumor HI efficacy. The primary risk is regulatory: FDA may require an additional controlled trial despite BTD, and no approved competitor currently blocks the path but diazoxide and octreotide remain entrenched standards of care.
Focus
upLIFT Phase 3 tumor HI topline results readout
H2 2026
Bull
If the full 16-participant cohort sustains the interim response rate — with the majority achieving ≥50% GIR reduction and complete IV glucose discontinuation — ersodetug would have a compelling single-arm dataset sufficient for an accelerated or traditional NDA submission in tumor HI. This would validate the streamlined open-label design agreed with FDA, establish the first approved pharmacologic option for a life-threatening orphan condition, and substantially de-risk the overall ersodetug franchise while the congenital HI regulatory pathway is resolved.
Bear
The primary failure mode is enrollment dilution: the 8 remaining participants could respond at a materially lower rate than the interim cohort, pulling the overall response rate below the threshold needed to support a marketing application. Additional safety signals or adverse events in a heavily ill, metastatic patient population could further complicate the benefit-risk profile. The single-arm open-label design, while FDA-agreed, leaves the dataset vulnerable to regulatory skepticism without a concurrent control arm, particularly if response durability is insufficient.
Unlock the full thesis for RZLT.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.